Page last updated: 2024-12-05

D-ribofuranose

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

ribofuranose : A cyclic ribose having a 5-membered tetrahydrofuran ring; the predominant (C3'-endo) form of the two cyclic structures (the other is the "C2'-endo" form, having a 6-membered ring) adopted by ribose in aqueous solution. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5779
CHEMBL ID444125
CHEBI ID47013
SCHEMBL ID27218

Synonyms (33)

Synonym
alpha-d-ribose-5
C00121
613-83-2
CHEBI:47013 ,
d-ribofuranose ,
smr000857325
MLS001335979
MLS001335980
AC-11298
R0025
(3r,4s,5r)-5-(hydroxymethyl)oxolane-2,3,4-triol
NCGC00247056-01
ribofuranose
CHEMBL444125
AKOS015918149
HMS2230E04
15761-67-8
EPITOPE ID:149136
SCHEMBL27218
alpha,beta-d-ribofuranose
HMFHBZSHGGEWLO-SOOFDHNKSA-N
AC-11299
AC-32439
ribofuranose (7ci,8ci,9ci)
ribofuranoside
rel-(3r,4s,5r)-5-(hydroxymethyl)tetrahydrofuran-2,3,4-triol
Q179271
d-ribofuranose (closed ring structure, relative stereochemistry)
DTXSID201317333
EN300-365473
d ribos
HY-113375
CS-0062320
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
ribofuranoseA cyclic ribose having a 5-membered tetrahydrofuran ring; the predominant (C3'-endo) form of the two cyclic structures (the other is the "C2'-endo" form, having a 6-membered ring) adopted by ribose in aqueous solution.
D-riboseA ribose in which the chiral carbon atom furthest away from the aldehyde group (C4') has the same configuration as in D-glyceraldehyde.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (38)

PathwayProteinsCompounds
Metabolism14961108
Carbohydrate metabolism173120
Pentose phosphate pathway1330
Regulation of leaf development1722
Pentose Phosphate Pathway1527
Glucose-6-phosphate Dehydrogenase Deficiency1527
Ribose-5-phosphate Isomerase Deficiency1527
Transaldolase Deficiency1527
Ribose Degradation58
NAD Metabolism1435
AMP Degradation (Hypoxanthine Route)413
cis-Zeatin-O-Glucoside Biosynthesis313
cis-Zeatin-N-Glucoside Biosynthesis314
Pentose phosphate cycle ( Pentose phosphate cycle )2225
Arsenate Detoxification716
pyridine nucleotide cycling (plants)022
caffeine biosynthesis I012
caffeine biosynthesis II (via paraxanthine)012
theobromine biosynthesis I09
adenosine nucleotides degradation I227
purine nucleotides degradation I (plants)234
pyrimidine ribonucleosides salvage III613
superpathway of pyrimidine ribonucleosides salvage2237
pyrimidine ribonucleosides salvage II812
guanine and guanosine salvage II27
adenine and adenosine salvage II415
cis-zeatin biosynthesis19
superpathway of guanosine nucleotides degradation (plants)227
guanosine nucleotides degradation II125
guanosine nucleotides degradation I226
superpathway of purines degradation in plants645
ribose phosphorylation210
pyrimidine ribonucleosides degradation II28
nicotinamide riboside salvage pathway II15
pyrimidine salvage pathway611
purine nucleosides salvage II (plant)613
AtMetExpress overview0109
Biochemical pathways: part I0466
Trans-zeatin biosynthesis022

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency5.62340.044717.8581100.0000AID485294
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (14)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1711518Growth inhibition of Caenorhabditis elegans N2 L1 larvae under monoxenic condition with Escherichia coli food assessed as reduction in body size at 42 mM incubated for 72 hrs by microscopic method relative to control2016Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3
Growth inhibitory effect of D-arabinose against the nematode Caenorhabditis elegans: Discovery of a novel bioactive monosaccharide.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (16.67)29.6817
2010's4 (66.67)24.3611
2020's1 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 50.61

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index50.61 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.30 (4.65)
Search Engine Demand Index74.47 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (50.61)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]